ArticleCancer science2010
Alternative lengthening of telomeres in hTERT-inhibited laryngeal cancer cells.
Article in Cancer science, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 23 citations in OpenAlex.
- Cancer stem cell mechanisms and targeted therapeutic strategies in head and neck squamous cell carcinoma.Cancer letters · 2025Review
- Effects of p53 and ATRX inhibition on telomeric recombination in aging fibroblasts.Frontiers in oncology · 2024Article
- [Research Advances of RAD51AP1 in Tumor Progression and Drug Resistance].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Review
- Role of telomere length in human carcinogenesis (Review).International journal of oncology · 2023Review
- Age-specific oncogenic pathways in head and neck squamous cell carcinoma - are elderly a different subcategory?Cellular oncology (Dordrecht, Netherlands) · 2022Review
- Functional characterization of miR-708 microRNA in telomerase positive and negative human cancer cells.Scientific reports · 2021Article
- Non-invasive assessment of telomere maintenance mechanisms in brain tumors.Nature communications · 2021Article
- Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.Frontiers in immunology · 2021Review
- The Role of Alternative Lengthening of Telomeres Mechanism in Cancer: Translational and Therapeutic Implications.Cancers · 2020Review
- Differential requirements for DNA repair proteins in immortalized cell lines using alternative lengthening of telomere mechanisms.Genes, chromosomes & cancer · 2017Article
- miR-380-5p-mediated repression of TEP1 and TSPYL5 interferes with telomerase activity and favours the emergence of an "ALT-like" phenotype in diffuse malignant peritoneal mesothelioma cells.Journal of hematology & oncology · 2017Article
- Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications.Cancer metastasis reviews · 2016Review
- Telomere elongation chooses TERRA ALTernatives.RNA biology · 2015Review
- Telomeric repeat-containing RNA TERRA: a noncoding RNA connecting telomere biology to genome integrity.Frontiers in genetics · 2015Review
- RNaseH1 regulates TERRA-telomeric DNA hybrids and telomere maintenance in ALT tumour cells.Nature communications · 2014Article
- Zscan4 interacts directly with human Rap1 in cancer cells regardless of telomerase status.Cancer biology & therapy · 2014Article
- Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science.Expert review of molecular diagnostics · 2014Review
- Twisted epithelial-to-mesenchymal transition promotes progression of surviving bladder cancer T24 cells with hTERT-dysfunction.PloS one · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In most human malignancies, telomere homeostasis is maintained by the reactivation of telomerase. While inhibiting telomerase provides a novel approach to the treatment of many cancers, telomere maintenance can occur in the absence of telomerase activity by the alternative lengthening of telomeres (ALT) mechanism. Therefore, it must be determined if inhibiting telomerase selects for cancer cells that activate ALT. Here, we report that Hep-2 cells that survived anti-telomerase treatments showed sustained proliferation in culture with down-regulated human telomerase reverse transcriptase (hTERT) expression and significantly enhanced levels of ALT-specific promyelocytic leukemia (PML) bodies. Analysis of the telomere lengthening kinetics also demonstrated elevated telomeric sister-chromatid exchange (T-SCE) in surviving Hep-2 cells, consistent with their long and heterogeneous telomeres. Similar to ALT cells, the surviving cells showed evidence of ALT telomere homeostasis. Furthermore, proteomic analysis identified several proteins differentially expressed between the untreated Hep-2 cells and surviving cells that may provide new insight for understanding these two telomere maintenance mechanisms. Thus, the findings in this study may help to improve telomerase-based therapy for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.